[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alexandria University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":637},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,44,68,98,127,155,179,207,240,265,289,314,343,369,389,412,435,460,479,501,519,536,570,595,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651388","clinical-outcomes-of-transconjunctival-vs-transcutaneous-approaches-in-orbital-fracture-repair-100651388",false,"NCT07759440","Clinical Outcomes of Transconjunctival Vs Transcutaneous Approaches in Orbital Fracture Repair","Clinical Outcomes of Transconjunctival Vs Transcutaneous Approaches in Orbital Fracture Repair : ( Randomized Clinical Trial)","Vs: versus","Inclusion Criteria:\n\nPatient with orbital fractures (e.g., orbital floor or zygomaticomaxillary complex fractures) require open reduction with internal fixation.\n\n• Adult patient between 20 and 50 years with no gender predilections.\n\nExclusion Criteria:\n\n* • Existing lacerations in the inferior and lateral periorbital regions.\n\n  * Comminuted fracture with bone loss.\n  * Existence of infection at the fracture line.\n  * Presence of acute or chronic conjunctival diseases.",true,"ALL","20 Years","50 Years",{"count":23,"type":24},75,"ESTIMATED","INTERVENTIONAL",[27],"NA","Open reduction and internal fixation of zygomaticomaxillary complex (ZMC) fractures has a challenging impact on the selection of the suitable surgical approach to the orbital and zygomatic skeleton. Precise repair of the ZMC fractures needs a quite understanding of the regional anatomy, precise diagnosis, an accessible exposure, and an accurate rigid fixation of fracture to restore the normal form. The aesthetic results are one of the most important requirements for these incisions in facial fracture reduction. Conventional approaches to the infraorbital rim\u002Forbital floor include transcutaneous as subciliary, subtarsal and infraorbital incisions and transconjunctival incision. A thorough understanding of each incisional technique requires an appreciation of the relevant anatomy putting in considerations the risk of associated complications.\n\nAim of this study:To compare between transconjunctival approach and transcutaneous approaches in open reduction of zygomaticomaxillary fracture.\n\nMaterials and methods: A study will be made on 75 patients who will undergo fracture repair of the zygomaticomaxillary complex. Twenty five of them (group A) will be treated via a subtarsal approach while. Other Twenty five patients (group B) via a transconjunctival approach. The remaining Twenty five patients (Group C) will be treated via infraorbital appeoach. Postoperative patient evaluation will be performed with specific attention paid towards, accessibility, the exposure duration (time from incision till exposure of the field), esthetic appearance ,postoperative pain, postoperative edema , wound healing, scaring, infection and postoperative ocular complications such as ectropion, entropion, scleral show and corneal abrasion. Postoperatively clinical examination along with radiographic examination will be done to evaluate the position of the zygoma and determine the adequacy of fracture reduction.\n\nResults: will be statistically analyzed using the IBM Statistical Package for Social Science (SPSS) software version 22.0",[30],"Orbital Fractures","RECRUITING","2026-08-06",{"date":34,"type":35},"2026-08-12","ACTUAL",{"date":37,"type":35},"2026-05-25",{"date":39,"type":24},"2026-11-25",{"name":41,"class":42},"Alexandria University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":25,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100650752","aesthetic-masking-and-resin-infiltration-time-in-mih-affected-incisors-100650752","NCT07753070","Aesthetic Masking and Resin Infiltration Time in MIH-affected Incisors","Effectiveness of Transillumination-Guided Surface Pretreatment on Aesthetic Masking and Resin Infiltration Time in MIH-affected Incisors (A Randomised Clinical Trial)","Inclusion Criteria:\n\n* Healthy children with MIH-related mild white creamy opacities on permanent incisors, code 1 according to the European Academy of Paediatric Dentistry (EAPD) criteria.\n* Clinically detectable isolated lesions (whether homogeneous or heterogeneous on the incisal and middle thirds of the buccal surface of the selected teeth.\n* Patients with score 3 (positive) or score 4 (definitely positive) according to Frankl behavioral rating scale\n* Parents or legal guardians accepting to sign a written consent and join the study\n\nExclusion Criteria:\n\n* MIH-affected permanent incisors with post-eruptive enamel breakdown, cavitated lesions, restorations, or previously treated with surface layer removal or remineralising agents in the previous six months.\n* Children with an allergy history","8 Years","13 Years",{"count":54,"type":24},100,[27],"Background: Resin infiltration often shows unpredictable outcomes in teeth affected by molar incisor hypomineralisation (MIH) due to variable enamel porosities, hypermineralised surface layers, and elevated protein content. Different pretreatment modalities alongside modified resin infiltration protocols have been suggested to enhance aesthetic masking and the required resin infiltration time.\n\nAim: To compare the effectiveness of transillumination-guided 5.25% NaOCl pretreatment following macroabrasion, with macroabrasion alone, each with 10-second hydrochloric acid (HCl) etching intervals, on aesthetic masking and resin infiltration time required in MIH-affected incisors.",[58],"Molar Incisor Hypomineralization","NOT_YET_RECRUITING","2026-08-04",{"date":62,"type":35},"2026-08-07",{"date":64,"type":24},"2026-08-10",{"date":66,"type":24},"2027-03-30",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":25,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100650215","olanzapine-based-dexamethasone-sparing-regimen-for-breast-cancer-patients-with-metabolic-risk-factors-100650215","NCT07743827","Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors","Efficacy of an Olanzapine Based Dexamethasone-sparing Regimen in Breast Cancer Patients With Metabolic-risk Factors: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Female patients ≥18 years.\n* Stage I-III breast cancer.\n* Scheduled to receive AC chemotherapy.\n* Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome).\n* ECOG performance status ≤2.\n\nExclusion Criteria:\n\n* Recent systemic corticosteroid use.\n* Active nausea or vomiting before chemotherapy.\n* Severe renal or hepatic impairment.\n* Uncontrolled diabetes or hypertension.\n* Psychiatric illness affecting adherence.\n* Pregnancy or lactation.\n* Active infections or inflammatory diseases.\n* Participation in another clinical trial","FEMALE","18 Years","70 Years",{"count":79,"type":24},90,[27],"The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.",[83,84,85],"Olanzapine","Breast Cancer","Dexamethasone",[87,88,89,90],"dexamethasone-sparing regimen","olanzapine","metabolic-risk factors","breast cancer patients","2026-07-29",{"date":60,"type":35},{"date":94,"type":35},"2026-05-10",{"date":96,"type":24},"2027-10-15",{"name":41,"class":42},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":19,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":25,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":43},"100648564","vexus-and-assessment-of-dry-weight-of-patients-on-hemodialysis-100648564","NCT07721636","VEXUS and Assessment of Dry Weight of Patients on Hemodialysis","Contribution of Lung Ultrasound and VExUS Score in Assessment of Volume Status in Maintenance Hemodialysis Patients.","Inclusion Criteria:\n\n* ESRD patients on maintenance HD for more than three months.\n* In the HD unit at the Medical Research Institute and Faculty of Medicine. Alexandria University.\n* Age: 25 -65 years old.\n* The ability to give informed consent.\n\nExclusion Criteria:\n\n* Patients with previous echocardiographic evidence of right heart dysfunction, tricuspid valve disease, or IVC thrombosis.\n* Patients with liver cirrhosis\n* Lung diseases: interstitial lung diseases, COPD patients.\n* Obese (BMI≥30)","25 Years","65 Years",{"count":108,"type":24},40,[27],"This is a prospective, single-arm study that will be conducted over a period of 24 weeks. The same maintenance HD patients will be followed sequentially in two study phases, with each patient serving as their own control.\n\nThe study aims to evaluate the role of POCUS, including LUS and VExUS score, in improving the assessment of volume status and determination of dry weight in patients undergoing maintenance HD.\n\nPhase I (Weeks 1-12): Clinical Assessment Phase During the first 12 weeks, all patients will be managed using standard clinical assessment alone. Determination of dry weight and calculation of target ultrafiltration (UF) will rely primarily on clinical parameters, including physical examination and routine clinical judgment.\n\nPhase II (Weeks 13-24): POCUS-guided assessment period During the second 12 weeks, the same patients will undergo POCUS assessment, including LUS and VExUS Score.\n\nLUS and VExUS examinations will be performed 30 minutes after the scheduled hemodialysis session. All measurements will be conducted during the mid-week dialysis session to reflect the average hydration status of each patient.\n\nAt the end of each phase, the results of all patients will be correlated with assessment of dry weight by BIS (Inbody version 720).\n\nInclusion criteria:\n\nESRD patients on maintenance HD for more than three months. In the HD unit at Medical Research Institute and Faculty of Medicine. Alexandria University.\n\nAge: 25 -65 years old. The ability to give informed consent.\n\nExclusion criteria:\n\n* Patients with previous echocardiographic evidence of right heart dysfunction, tricuspid valve disease, or IVC thrombosis.\n* Patients with liver cirrhosis\n* Lung diseases: interstitial lung diseases, COPD patients.\n* Obese (BMI≥30) Before inclusion in the study, all patients will be required to fill out a written informed consent. Also, approval from the Medical Ethics Committee will be obtained. Maintenance hemodialysis patients.",[112,113],"Hemodialysis Patient","Dry Weight",[115,116,117,118],"dry weight","POCUS","Hemodialysis","VExUS","2026-07-18",{"date":121,"type":35},"2026-07-23",{"date":123,"type":35},"2026-07-01",{"date":125,"type":24},"2027-02-28",{"name":41,"class":42},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":25,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":43},"100648012","effect-of-targeting-upper-normal-serum-magnesium-levels-on-norepinephrine-requirements-in-septic-shock-patients-100648012","NCT07716956","Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients","Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Male and female adult patients (aged ≥18 years) diagnosed with septic shock.\n* Resistant septic shock that requires corticosteroids.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Baseline hypermagnesemia (serum magnesium level \\> 2.3 mg\u002FdL).\n* Renal impairment with creatinine clearance (CrCl) \\\u003C 10 ml\u002Fmin.\n* Mixed shock.",{"count":135,"type":24},60,[27],"The goal of this clinical trial is to assess the effect of targeting upper normal serum magnesium levels on norepinephrine requirements in adult patients with septic shock.\n\nThe main questions it aims to answer are:\n\n1. Does maintaining upper normal serum magnesium levels lower the total cumulative dose and duration of norepinephrine therapy?\n2. Does this approach reduce the intensive care unit (ICU) length of stay, duration of mechanical ventilation and mortality?\n\nThis study will compare an intervention group to a control group to see the effect of targeting upper normal serum magnesium levels.\n\nParticipants will:\n\n* Have their serum magnesium levels assessed at baseline (Day 0), at three-day intervals (Days 3, 6, 9) thereafter and on the day of norepinephrine discontinuation.\n* Receive individualized intravenous magnesium sulfate infusions to achieve and maintain the target serum magnesium levels.\n* Have their demographic data collected and be monitored closely for clinical data, vital signs, Mean Arterial Pressure (MAP), urine output and laboratory parameters.",[139,140],"Septic Shock","Sepsis",[142,143,144,145,146],"vasopressors","norepinephrine","magnesium sulfate","magnesium level","ICU ( Intensive Care Unit )","2026-07-16",{"date":149,"type":35},"2026-07-21",{"date":151,"type":24},"2026-07",{"date":153,"type":24},"2027-07",{"name":41,"class":42},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":25,"phases":163,"briefSummary":164,"conditions":165,"keywords":169,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100647881","effect-of-ai-assisted-expressive-writing-on-anxiety-emotional-distress-and-quality-of-life-among-patients-receiving-chemotherapy-100647881","NCT07713381","Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy","The Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy: A Mixed-Methods Study","Inclusion Criteria:\n\n* Adult patients aged 18 years and above.\n* Diagnosed with any type of cancer and currently receiving chemotherapy treatment.\n* Able to read and write Arabic.\n* Able to communicate and express thoughts and feelings.\n* Have access to a smartphone, tablet, or computer with internet connectivity.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with severe psychiatric disorders (e.g., psychosis or schizophrenia).\n* Having cognitive impairment that interferes with understanding or communication.\n* Currently receiving structured psychological therapy during the study period.\n* Unable to complete the study questionnaires or intervention sessions.\n* Refusal to participate or withdrawal from the study at any time.",{"count":54,"type":24},[27],"This study aims to evaluate the effect of an AI-assisted expressive writing intervention on anxiety, emotional distress, and quality of life among patients receiving chemotherapy. A mixed-methods, interventional research design will be employed. Participants will be assigned to either a study group receiving the AI-assisted expressive writing program in addition to routine care or a control group receiving routine care only. Quantitative data will be collected using the Depression Anxiety Stress Scale-21 (DASS-21) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Qualitative data will be obtained through semi-structured interviews to explore participants' experiences with the intervention. The findings are expected to provide evidence regarding the effectiveness of AI-assisted expressive writing as a supportive strategy for improving psychological well-being and quality of life among patients undergoing chemotherapy.",[166,167,168],"Cancer","Chemotherapy","Anxiety",[170,171,167],"Artificial Intelligence","AI-Assisted Expressive Writing",{"date":173,"type":35},"2026-07-20",{"date":175,"type":24},"2026-07-10",{"date":177,"type":24},"2026-09-10",{"name":41,"class":42},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":25,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":43},"100646370","intraperitoneal-dexmedetomidine-versus-magnesium-as-adjuvants-to-bupivacaine-in-laparoscopic-cholecystectomy-100646370","NCT07693621","Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy","Intraperitoneal Instillation of Dexmedetomidine Versus Magnesium Sulphate as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Patients aged 18-60 years\n* ASA physical status I-II\n* scheduled for elective laparoscopic cholecystectomy under general anesthesia.\n\nExclusion Criteria:\n\n* Known hypersensitivity to study drugs\n* history of cardiac arrhythmias or conduction abnormalities\n* severe hepatic\u002Frenal impairment\n* chronic opioid or analgesic use\n* pregnancy\n* conversion to open surgery\n* drain insertion.","60 Years",{"count":188,"type":24},80,[27],"Although both dexmedetomidine and magnesium sulphate have been individually evaluated as adjuvants to local anesthetics, direct comparisons between the two agents in intraperitoneal instillation during laparoscopic cholecystectomy remain limited. Understanding their relative efficacy and safety could provide valuable guidance for optimizing perioperative analgesia in these patients.",[192,193,194],"Dexmedetomidine","Magnesium Sulfate","Laparoscopic Cholecystectomy",[196,197,198],"bupivacaine","dexmedetomidine","cholecystectomy","2026-07-04",{"date":201,"type":35},"2026-07-09",{"date":203,"type":35},"2026-05-03",{"date":205,"type":24},"2027-01-01",{"name":41,"class":42},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":106,"enrollmentInfo":214,"targetDuration":4,"studyType":25,"phases":216,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":43},"100616063","comparing-diosmin-hesperidin-and-loratadine-to-prevent-bone-pain-from-g-csf-in-patients-with-blood-cancers-100616063","NCT07300735","Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Adults 18 to 65 years old\n* Receiving a G-CSF for one of the following indications:\n\nTreatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant\n\n* Patients with or without bone pain associated with G-CSF administration.\n* Willingness to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with solid tumors.\n* Pregnant or breastfeeding women.\n* Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.\n* Patients with pre-existing bone disorders or receiving bone modifying agents\n* Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.\n* Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim\n* Patients who are unable to understand or provide informed consent",{"count":215,"type":24},88,[27],"This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.\n\nThe study is comparing two oral medications for their effectiveness as a preventive treatment:\n\n* Diosmin-Hesperidin (a flavonoid supplement).\n* Loratadine (a common anti-allergy medication).\n\nThe core question the study is trying to answer is:\n\n* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine?\n* Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?",[219,220,221],"Hematologic Malignancy","Neutropenia","Bone Pain",[223,224,225,226,227,228,229,230,231,232],"Loratadine","Diosmin","Filgrastim","Granulocyte Colony Stimulating Factor","G-CSF Induced Bone Pain","Hesperidin","Flavonoid","Antihistamine","Prophylaxis","Randomized Controlled Trial","2026-06-23",{"date":235,"type":35},"2026-06-24",{"date":237,"type":35},"2025-03-01",{"date":153,"type":24},{"name":41,"class":42},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":25,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":43},"100644774","ai-based-tai-chi-and-baduanjin-for-improving-balance-and-reducing-fall-risk-in-adults-with-chronic-diseases-100644774","NCT07672704","AI-Based Tai Chi and Baduanjin for Improving Balance and Reducing Fall Risk in Adults With Chronic Diseases","Comparative Effects of an AI-Based Mobile Application Delivering Tai Chi and Baduanjin on Balance and Fall Risk in Adults With Chronic Diseases: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults\n* Individuals with one or more health conditions relevant to the study\n* Able to participate in physical activity\n* Able to understand study instructions\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* \\- Any condition that may limit safe participation in the study\n* Any medical or other issue that may interfere with study procedures, as determined by the research team",{"count":248,"type":24},120,[27],"This study aims to examine the effects of an AI-based mobile application delivering Tai Chi and Baduanjin exercises on balance and fall risk in adults with chronic diseases.\n\nParticipants will be randomly assigned to Tai Chi, Baduanjin, or a control group over a 12-week period. The AI application will provide exercise guidance and basic feedback.\n\nOutcomes will focus on balance and, fall risk, along with user interaction with the technology.\n\nThe results are expected to support the use of AI-assisted exercise programs in improving balance and reducing fall risk in individuals with chronic conditions.",[252,253],"Chronic Diseases","Balance Disorders",[255,256,170],"Tai Chi","Baduanjin","2026-06-22",{"date":259,"type":35},"2026-06-29",{"date":261,"type":24},"2026-06-16",{"date":263,"type":24},"2026-07-30",{"name":41,"class":42},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":18,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":275,"conditions":276,"keywords":279,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":43},"100642164","organizational-readiness-and-barriers-to-adoption-of-female-external-urinary-devices-in-hospitals-100642164","NCT07656701","Organizational Readiness And Barriers To Adoption Of Female External Urinary Devices In Hospitals","Organizational Readiness And Barriers To The Adoption Of Female External Urinary Collection Devices: A Multicenter Mixed-Methods Study In Resource-Constrained Healthcare Settings","Inclusion Criteria:\n\n* Registered nurses, staff nurses, or head nurses\n* Currently working in clinical settings (e.g., ICU, medical, or surgical units)\n* Direct involvement in patient care\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Nurses on extended leave during the data collection period\n* Incomplete questionnaire responses",{"count":273,"type":24},200,"OBSERVATIONAL","This study aims to assess organizational readiness and explore perceived barriers and facilitators influencing the adoption of female external urinary collection devices among nurses in healthcare settings. Using a mixed-methods approach, the study examines individual, organizational, and contextual factors that may impact implementation.",[277,278],"Healthcare Technology Adoption","Organizational Readiness",[280,278,281],"Female External Urinary Collection Devices","Barriers and Facilitators","2026-06-17",{"date":257,"type":35},{"date":285,"type":24},"2026-06-18",{"date":287,"type":24},"2026-07-15",{"name":41,"class":42},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":77,"enrollmentInfo":296,"targetDuration":4,"studyType":25,"phases":297,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":43},"100574595","right-versus-left-distal-axillary-vein-cannulation-100574595","NCT06761326","Right Versus Left Distal Axillary Vein Cannulation","Right Versus Left Ultrasound-Guided Distal Axillary Vein Cannulation : A Prospective Randomized Study","Inclusion Criteria:\n\n.Patients requiring porta Cath insertion.\n\nExclusion Criteria:\n\n* Abnormalities in the platelet count or coagulation\n* Thrombosis of the target vein\n* Soft tissue infection of the overlying area\n* Fracture of the clavicle or proximal ribs\n* Patients with pacemakers or defibrillators\n* Malignant superior vena cava syndrome\n* Gross obesity\n* History of prior catheterization of the subclavian vein\n* Patient refusal to participate in the study.",{"count":188,"type":24},[27],"Central venous cannulation is an essential procedure in the anaesthetic and critical care practice. Ultrasound has revolutionized the practice favoring the internal jugular cannulation to the other sites .Subcalvian vein cannulation has fallen out of favor mainly due to the difficult visualization with the ultrasound, especially in obese patients and the inevitable position of the clavicle acting as a bony obstacle , in addition to the anatomical position in vicinity to the pleura which might raise the risk of pneumothorax . Indeed the subclavian vein cannulation is more comfortable and tolerated by the patient especially those requiring long term intravenous therapy, with less rates of infection and thrombosis. This mandated the development of a safer and efficient technique for the cannulation empowered by the ultrasound technology.\n\nThe infracalvicular approach or the proximal axillary vein cannulation has been described but is not popular. It provides a potentially safer and successful technique with less complication both in \"experienced\" and \"less experienced\"operators . All the patients will receive general anaesthesia with laryngeal mask insertion . Careful sterilization of the surgical site and strict aseptic techniques for the handling of the ultrasound probe will be pursued",[300,301],"Infraclavicular Vein Cannulation","Venous Cannulation",[303,304,305,306,307],"subclavian vein cannulation","ultrasound guided","fluroscopy","maldirection","infraclavicular approach",{"date":282,"type":35},{"date":310,"type":35},"2024-10-21",{"date":312,"type":24},"2026-08",{"name":41,"class":42},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":25,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":43},"100641123","indocyanine-green-guided-versus-standard-laparoscopic-distal-pancreatectomy-for-pancreatic-body-and-tail-lesions-100641123","NCT07656571","Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions","Indocyanine Green Fluorescence-Guided Versus Standard Laparoscopic Distal Pancreatectomy: A Prospective Randomized Controlled Trial","ICG-LDP","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body mass index (BMI) ≤ 40 kg\u002Fm².\n* Radiologically confirmed lesion(s) of the pancreatic body and\u002For tail requiring elective distal pancreatectomy, with or without splenectomy.\n* Lesion amenable to a laparoscopic approach as determined by the operating surgeon on preoperative CT or MRI imaging.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Adequate hepatic function: serum bilirubin ≤ 2 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.\n* Patients who have received neoadjuvant chemotherapy, chemoradiotherapy, or radiotherapy are eligible if resectability is confirmed on restaging imaging and at least 3 weeks have elapsed since the last treatment dose.\n* Ability to provide written informed consent and willingness to comply with study follow-up.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to indocyanine green (ICG), iodine, or iodinated contrast agents.\n* Uncorrected coagulopathy (international normalized ratio \\> 1.5 or platelet count \\\u003C 80 × 10⁹\u002FL).\n* Pregnancy or breastfeeding.\n* Prior major upper abdominal surgery precluding safe laparoscopic access (for example previous pancreatectomy or gastrectomy) as judged by the surgeon.\n* Presence of distant metastases or locally advanced disease requiring vascular resection at the time of surgery.\n* American Society of Anesthesiologists (ASA) physical status classification IV or V.\n* Severe hepatic impairment (Child-Pugh class C).\n* Inability or unwillingness to comply with scheduled follow-up visits and assessments.\n* Concurrent participation in another interventional clinical trial.",{"count":323,"type":24},72,[27],"Postoperative pancreatic fistula is the most important complication after laparoscopic distal pancreatectomy for tumors of the body and tail of the pancreas. It can cause infection, bleeding, longer hospital stay, and even death. New imaging technology using indocyanine green (ICG) dye and near-infrared fluorescence may help surgeons see blood flow to the pancreatic stump, spleen, and nearby vessels during surgery and make safer decisions about where to cut and which structures to preserve.\n\nThis study will compare two standard laparoscopic operations for pancreatic body and tail lesions: one with ICG fluorescence imaging at key steps of the procedure and one without ICG imaging. Adult patients who need elective laparoscopic distal pancreatectomy will be randomly assigned to one of the two groups. All other aspects of care before, during, and after surgery will be the same.\n\nThe main goal is to find out whether using ICG fluorescence can reduce the rate of clinically relevant postoperative pancreatic fistula (Grade B or C) within 90 days after surgery. Secondary goals include comparing blood loss, operating time, need to convert to open surgery, spleen preservation, complications, hospital stay, and oncologic outcomes such as margin status and lymph node yield.",[327,328],"Pancreatic Neoplasms","Pancreatic Cancer",[330,331,332,333,334,335],"Laparoscopic distal pancreatectomy","Distal pancreatectomy","Pancreatic body and tail lesions","Pancreatic ductal adenocarcinoma","ICG fluorescence imaging","ICG-guided surgery","2026-06-15",{"date":285,"type":35},{"date":339,"type":35},"2026-06-09",{"date":341,"type":24},"2027-02-01",{"name":41,"class":42},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":368},"100637172","socio-ecological-determinants-and-health-literacy-a-path-analysis-of-self-management-agency-among-patients-with-diabetes-mellitus-100637172","NCT07591103","Socio-Ecological Determinants and Health Literacy: A Path Analysis of Self-Management Agency Among Patients With Diabetes Mellitus","Socio-Ecological Determinants and Health Literacy as Predictors of Self-Management Agency Among Patients With Diabetes Mellitus: A Cross-Sectional Path Analysis Study","Inclusion Criteria:\n\n* \\- Adults aged 18 years and older.\n* Diagnosed with type 1 or type 2 diabetes mellitus.\n* Receiving follow-up care in outpatient or primary healthcare settings.\n* Able to communicate verbally and provide informed consent.\n\nExclusion Criteria:\n\n* \\- Patients with severe cognitive impairment.\n* Patients with acute medical conditions preventing participation.\n* Pregnant women diagnosed with gestational diabetes.",{"count":351,"type":24},400,"This study aims to examine the relationships between socio-ecological determinants, health literacy, and self-management agency among patients with diabetes mellitus. Using a path analysis framework, the study investigates how multi-level socio-ecological factors and different dimensions of health literacy influence patients' capacity for diabetes self-management. Understanding these pathways will support the development of comprehensive, context-sensitive interventions to improve diabetes outcomes.",[354],"Diabetes Mellitus (Type 1 and Type 2)",[356,357,358,359,360],"Diabetes Mellitus","Health Literacy","Self-Management","Socio-Ecological Determinants","Self-Care Agency","2026-06-04",{"date":363,"type":35},"2026-06-05",{"date":365,"type":35},"2026-05-15",{"date":263,"type":24},{"name":41,"class":42},2,{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":376,"targetDuration":4,"studyType":25,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":43},"100639578","three-photobiomodulation-wavelengths-635-940-and-1064-nm-on-chronic-myogenic-temporomandibular-disorder-100639578","NCT07626164","Three Photobiomodulation Wavelengths (635, 940, and 1064 nm) on Chronic Myogenic Temporomandibular Disorder","Efficacy of Three Photobiomodulation Wavelengths (635, 940, and 1064 nm) on Chronic Myogenic Temporomandibular Disorder A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients suffering from chronic myogenic TMD based on diagnostic criteria for diagnosis of temporomandibular joint disorders (DC\u002FTMD) criteria. (pain increases with jaw opening, chewing, or clenching).\n* Patients suffering of unilateral or bilateral chronic pain (\\> 3 months' duration) related to masseter and temporalis muscles(30).\n* Patients suffering of moderate-to-severe pain intensity ≥ 4 on a 0-10 VAS\n* Patients that have not responded to conservative modes of treatment during the study and up to 3 months after last intervention. (medications, physiotherapy, splints).\n\nExclusion Criteria:\n\n* Patients suffering from chronic systematic conditions that alter pain sensitivity; neurological diseases, pain of dental origin, pregnancy or lactation, high blood pressure, diabetes milletus, rheumatic inflammatory disease, fibromyalgia, obstructive sleep apnea, and restrictions for the use of laser (pacemakers).\n* Participants on medications that affect pain sensitivity and perception during the last 2 weeks: anticoagulants, analgesics, or antidepressants.\n* History of surgery, arthropathy (joint disorders), facial trauma, malignant tumors or fractures in the orofacial region, neuropsychological or hormonal problems\n* Treatments: orthodontics, splints, major occlusal rehabilitation, prosthodontic therapy, previous PBM, TENS therapy, or botox for TMD in the last 6 months.",{"count":377,"type":24},45,[27],"Temporomandibular disorders (TMDs) are among the most common musculoskeletal conditions associated with chronic orofacial pain and functional disability. Chronic Myogenic TMD (MTMD) is the most prevalent subtype and is characterized by persistent masticatory muscle pain driven by peripheral and central sensitization mechanisms. Photobiomodulation (PBM) represents a conservative, non-invasive therapeutic modality within the medical management of TMD; however, the wavelength-dependent clinical and muscular effects remain inadequately defined. Aim: To compare the efficacy of three PBM wavelengths (635, 940, 1,064 nm) on pain intensity, mandibular function, surface electromyographic activity (sEMG), and pressure pain threshold (PPT) in patients with chronic myogenic TMD.",[381],"Temporomandibular Disorders","2026-06-02",{"date":361,"type":35},{"date":385,"type":24},"2026-06-01",{"date":387,"type":24},"2026-12-30",{"name":41,"class":42},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":19,"minAge":395,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":25,"phases":398,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":43},"100638926","a-robotic-mental-health-simulation-intervention-to-enhance-professional-identity-interpersonal-communication-competence-and-emotional-intelligence-among-saudi-nursing-students-a-quasi-experimental-study-100638926","NCT07627646","A Robotic Mental Health Simulation Intervention to Enhance Professional Identity, Interpersonal Communication Competence, and Emotional Intelligence Among Saudi Nursing Students: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Undergraduate nursing students enrolled in the Psychiatric-Mental Health Nursing course (NURS 224) during the study period Students registered in the Bachelor of Science in Nursing program at the College of Nursing, University of Hafr Al Batin Willingness to participate in the study and provide informed consent Attendance in both theoretical and practical components of the course during the intervention period Availability to participate in simulation sessions and complete all study assessments at baseline, post-test, and follow-up\n\nExclusion Criteria:\n\n* Students who refuse or withdraw consent at any stage of the study Students who fail to complete all required data collection points (pre-test, post-test, and follow-up) Students absent from the robotic simulation sessions or traditional teaching sessions during the intervention period Students with prior formal training or extensive experience in psychiatric simulation-based education (if applicable to avoid bias)","17 Years","27 Years",{"count":188,"type":24},[27],"A quasi-experimental pre-test, post-test, and three-month follow-up design will be used. Nursing students assigned to the intervention group will participate in structured robotic mental health simulation sessions involving interactions with a robot programmed to portray patients experiencing common psychiatric conditions, while the control group will receive traditional teaching methods. Outcomes will be assessed using validated measures of professional identity, interpersonal communication competence, and emotional intelligence before the intervention, immediately after completion, and three months later to determine both immediate and sustained educational effects",[401,402,403],"Mental Health Simulation","Professional Identity","Interpersonal Communication Competence",[405],"Mental Health Simulation Intervention; Professional Identity; Interpersonal Communication Competence; Emotional Intelligence","2026-05-31",{"date":361,"type":35},{"date":409,"type":35},"2025-07-15",{"date":336,"type":24},{"name":41,"class":42},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":19,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":25,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":43},"100639520","brainwave-entrainment-technique-in-managing-anxiety-and-pain-perception-in-pediatric-dental-patients-100639520","NCT07617662","Brainwave Entrainment Technique in Managing Anxiety and Pain Perception in Pediatric Dental Patients.","Effectiveness of Brainwave Entrainment on Anxiety and Pain Perception in Pediatric Dental Patients (A Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* Participants enrolled in the study will be selected after fulfilling the following inclusion criteria:\n\n  1. Healthy six to nine years old.\n  2. Frankl behavioural rating score 2 during preoperative assessment\n  3. Bilateral mandibular primary molars indicated for extraction.\n  4. Written guardian consent.\n\nExclusion Criteria:\n\n* Children with:\n\n  1. Physical disabilities or psychiatric disorders\n  2. Epilepsy.\n  3. Visual or hearing disabilities\n  4. On photophobia inducing or hearing altering medications.\n  5. Hypersensitivity to local anesthetic drugs used.","6 Years","9 Years",{"count":422,"type":24},34,[27],"Pediatric dental anxiety and pain management present significant clinical challenges during routine treatment. While conventional behavior management techniques exist, their inconsistent effectiveness necessitates the continuous search for alternative solutions. Brainwave entrainment (BWE) , a novel approach using audiovisual stimuli to induce relaxing alpha waves (8-12 Hz) , shows promise in anxiety and pain management. However, its application in pediatric dentistry remains insufficiently explored, particularly for invasive dental procedures.",[426,427],"Pediatric Dental Anxiety","Pediatric Dental Pain","2026-05-29",{"date":385,"type":35},{"date":431,"type":24},"2026-05",{"date":433,"type":24},"2026-10",{"name":41,"class":42},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":19,"minAge":442,"maxAge":106,"enrollmentInfo":443,"targetDuration":4,"studyType":25,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":43},"100639377","erector-spina-plane-block-versus-modified-thoracoabdominal-nerve-block-after-laparoscopic-cholecystectomy-100639377","NCT07624058","Erector Spina Plane Block Versus Modified Thoracoabdominal Nerve Block After Laparoscopic Cholecystectomy","Erector Spinae Plane Block Versus Modified Thoracoabdominal Nerve Block For Pain Control After Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Age: between 30 - 65\n* American Society of Anaesthesiologists physical status: I- III\n* Body mass index: 18-35 kg.m-2\n\nExclusion Criteria:\n\n* Patient Refusal\n* Allergy to local anaesthetic agents.\n* Skin infection at the site of injection.\n* Coagulopathy.\n* Diabetes Mellitus","30 Years",{"count":444,"type":24},50,[27],"direct comparisons between ESPB and M-TAPA for postoperative analgesia after LC remain limited. This is an important area of clinical interest because the two blocks differ significantly in their anatomical targets, mechanism of analgesia, and likely dermatomal coverage. The ESPB provides analgesia through paravertebral spread affecting both dorsal and ventral rami, thereby offering posterior and visceral pain relief, whereas M-TAPA directly targets the thoracoabdominal nerves, resulting in better anterior and lateral abdominal wall analgesia. Understanding which technique offers superior or more balanced analgesia could help to optimise regional anaesthesia strategies in LC and to improve patient outcomes.",[448,449,194],"Erector Spinae Block","Modified Thoracoabdominal Nerve Block",[451,452],"pain control","erector spinae block",{"date":454,"type":35},"2026-06-03",{"date":456,"type":35},"2026-04-01",{"date":458,"type":24},"2027-03-01",{"name":41,"class":42},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":105,"enrollmentInfo":467,"targetDuration":4,"studyType":25,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":478,"locationsCount":43},"100639840","bone-metabolism-in-patients-treated-with-3d-printed-aligners-versus-thermoformed-aligners-100639840","NCT07617571","Bone Metabolism in Patients Treated With 3d Printed Aligners Versus Thermoformed Aligners","Bone Metabolism in Patients Treated With 3d Printed Aligners Versus Thermoformed Aligners (Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* Minor malocclusion (2 to 4 mm of crowding) .\n* Patients in need for Antero-posterior expansion and labial tipping of incisors without interproximal reduction\n* No use of anti-inflammatory drugs or antibiotics in the past 6 months.\n* Periodontal parameters of gingival index \\\u003C1 and no pocketing with a generalized pocketing depth of \\\u003C3mm.\n* Radiographic parameters of no crestal bone loss.\n* No history of smoking.\n\nExclusion Criteria:\n\n* Signs of inflammation of the gingiva, and periodontitis.\n* Systemic conditions (kidney disease, HIV, and liver disease).\n* Teeth missing or poor oral hygiene.\n* Bone disease e.g.; osteoporosis.",{"count":468,"type":24},30,[27],"Background: Orthodontic forces induce tissue reactions by triggering perturbations from orthodontic appliances, which lead to the modelling and remodelling of alveolar bone. Despite the growing popularity of 3D-printed aligners, no studies have compared their effects on bone metabolism in comparison with thermoformed aligners. Aim: This study aims to assess bone metabolism in patients undergoing treatment with 3D-printed aligners versus thermoformed aligners.",[472,473],"Bone Metabolism","Orthodontic Aligners","2026-05-24",{"date":385,"type":35},{"date":385,"type":24},{"date":123,"type":24},{"name":41,"class":42},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":19,"minAge":419,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":25,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":43},"100638878","external-oblique-intercostal-plane-block-versus-erector-spinae-plane-block-in-paediatric-upper-abdominal-surgeries-100638878","NCT07617545","External Oblique Intercostal Plane Block Versus Erector Spinae Plane Block in Paediatric Upper Abdominal Surgeries","Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Plane Block in Paediatric Upper Abdominal Surgeries","Inclusion Criteria:\n\n* Children aged between 6 and 12 years of both sex.\n* Patients with the American Society of Anesthesiologists (ASA) physical status I\u002FII.\n* Patients undergoing upper abdominal surgeries involving upper abdominal incisions.\n\nExclusion Criteria:\n\n* Guardian refusal.\n* Allergy to local anesthetics.\n* Surgical procedures exceeding 3 hours.\n* Infection at the area planned for the block injection.\n* Prolonged opioid medication.\n* Patients preoperatively medicated by Beta blockers","12 Years",{"count":108,"type":24},[27],"This study aims to compare between ultrasound guided external oblique intercostal plane block and ultrasound guided erector spinae plane block in paediatric upper abdominal surgeries.",[491,492,493,494],"External Oblique Intercostal Plane Block","Erector Spinae Plane Block","Pediatric","Upper Abdominal Surgeries",{"date":385,"type":35},{"date":497,"type":35},"2025-05-01",{"date":499,"type":24},"2026-10-01",{"name":41,"class":42},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":19,"minAge":442,"maxAge":186,"enrollmentInfo":508,"targetDuration":4,"studyType":25,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":516,"leadSponsor":518,"locationsCount":43},"100638154","periosteal-muscular-flap-in-reconstruction-of-small-and-medium-sized-defects-at-floor-of-the-mouth-100638154","NCT07590427","Periosteal Muscular Flap in Reconstruction of Small and Medium Sized Defects at Floor of the Mouth","the Versatility of Periosteal Muscular Flap in Reconstruction of Small and Medium Sized Defects at Floor of the Mouth","Inclusion Criteria:\n\n* Patients requiring reconstruction of small and medium sized FOM defects.\n\nExclusion Criteria:\n\n* Previous neck dissection.\n* Previous radiotherapy in the maxillofacial region.\n* Uncontrolled diseases that may contraindicate the surgery",{"count":509,"type":24},20,[27],"Background: Rebuilding head and neck defects is a chief challenge to the maxillofacial surgeons especially after cancer resection, trauma, infection and craniofacial deformities. Earlier, the use of obturators for many years has been a successful treatment plan. However, recently several surgical modalities are available for the restoration of such defects as locoregional or microvascular free flaps.\n\nAim: To assess the reliability of the lateral periosteal-muscular flap in the reconstruction of small and medium sized floor of the mouth defects.\n\nMain outcome: To evaluate functional outcomes (Including speech, tongue mobility, deglutition, flap viability), pain, complications such as trismus, flap necrosis, dehiscence, infection, fistula formation or donor site morbidity and aesthetic outcomes. Mean harvesting time and flap dimensions will be recorded.",[513],"Maxillofacial Reconstruction",{"date":365,"type":35},{"date":385,"type":24},{"date":517,"type":24},"2027-06-01",{"name":41,"class":42},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":25,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":535,"locationsCount":43},"100637616","high-intensity-laser-therapy-versus-low-level-laser-therapy-in-the-treatment-of-trigeminal-neuralgia-100637616","NCT07590414","High-intensity Laser Therapy Versus Low Level Laser Therapy in the Treatment of Trigeminal Neuralgia","High-intensity Laser Therapy Versus Low Level Laser Therapy in the Treatment of Trigeminal Neuralgia (a Randomized Clinical Trial)","Inclusion Criteria:\n\n* Patients diagnosed with trigeminal neuralgia according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria.\n* Patients with drug refractory trigeminal neuralgia (defined as poor response to adequate pharmacological treatment or intolerance to side effects for at least three months).\n* Patients who are contraindicated for surgical intervention or any other interventions, or who have previously undergone such interventions without obtaining satisfactory pain relief.\n\nExclusion Criteria:\n\n* patients with secondary trigeminal neuralgia diagnosed with brain lesions that is indicated for surgery (percutaneous procedures, gamma knife, microvascular decompression).\n* Patients with other orofacial conditions such as temporomandibular disorders, migraine, or other neurological diseases.\n* Patients with contraindications to laser use (e.g., pacemakers).\n* Patients who are responding well to medical treatment.\n* Pregnant or lactating women.",{"count":527,"type":24},38,[27],"Trigeminal neuralgia (TN) is the most common and severe type of neuropathic pain disorder affecting the orofacial region. It is characterized by sudden, intense, episodic attacks of pain in the distribution of trigeminal nerve, usually unilateral. The condition severely impairs patient's quality of life. TN represents a diagnostic and therapeutic challenge, pharmacological therapy remains the first-line management, and many patients experience reduced drug tolerance or significant side effects over time. Surgical options are considered for refractory cases but are invasive and carry risks such as infection, nerve damage, and recurrence of symptoms. In recent years, laser based therapies have gained attention as safe, non-invasive alternatives. Low level laser therapy (LLLT) promotes photo-biomodulation and nerve repair without thermal damage, while high-intensity laser therapy (HILT) can achieve deeper penetration and direct neuromodulation. However, comparative evidence regarding their efficacy in TN is still limited. Aim: The present study aims to evaluate and compare the effect of High intensity laser therapy and low level laser therapy in reducing pain intensity and improving quality of life in patients with trigeminal neuralgia.",[531],"Trigeminal Neuralgia",{"date":365,"type":35},{"date":365,"type":24},{"date":387,"type":24},{"name":41,"class":42},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":25,"phases":544,"briefSummary":545,"conditions":546,"keywords":551,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":368},"100633150","ai-guided-relaxation-for-hemodialysis-anxiety-100633150","NCT07522944","AI-Guided Relaxation for Hemodialysis Anxiety","Artificial Intelligence-Guided Relaxation Interventions for Reducing Anxiety and Enhancing Coping Strategies in Patients Undergoing Hemodialysis","Inclusion Criteria:\n\nAdult patients aged 18 years or older Confirmed diagnosis of end-stage renal disease (ESRD) receiving maintenance hemodialysis for at least 3 months to ensure treatment stability Conscious, oriented, and able to communicate effectively Documented baseline anxiety at a mild-to-moderate level confirmed on initial screening using the GAD-7 or HADS prior to enrollment Adequate visual and auditory functions sufficient to interact with the AI-guided relaxation platform Willing to participate and provide written informed consent prior to enrollment\n\nExclusion Criteria:\n\nHistory of epilepsy, chronic vertigo, or seizure disorders, as AI or VR visual stimuli may trigger adverse episodes Severe cognitive impairment or diagnosed psychiatric disorders such as dementia or schizophrenia that prevent comprehension of or adherence to study instructions Acute medical complications or hemodynamic instability occurring during the dialysis session Severe visual impairment or blindness precluding use of the digital relaxation interface Skin infections or injuries on the face or head preventing comfortable use of a headset where applicable Currently enrolled in any other psychological or relaxation intervention study",{"count":135,"type":24},[27],"This study aims to evaluate whether a relaxation program guided by Artificial Intelligence (AI) can help reduce anxiety and improve coping mechanisms for patients receiving maintenance hemodialysis. Patients undergoing dialysis often face significant psychological stress and physical discomfort. This research uses a randomized controlled trial (RCT) with a parallel-group, pretest-posttest controlled design to compare patient well-being before and after using the AI-guided intervention.\n\nParticipants will engage with an AI system designed to provide personalized relaxation techniques during their dialysis sessions. The study uses a mixed-methods approach. Quantitative: Researchers will use standardized scales to measure changes in anxiety levels, depression, coping strategies, and perceived relaxation. Qualitative: Researchers will conduct interviews with participants to understand their personal experiences, how they engaged with the AI technology, and how it influenced their ability to manage the stress of their treatment.",[547,168,548,549,550],"Renal Insufficiency, Chronic","Relaxation Therapy","Maintenance Hemodialysis","Stress, Psychological",[552,553,554,555,168,170,556,548,557,558,559,560,561],"Hemodialysis, Hospital","Renal Dialysis","End-Stage Renal Disease (ESRD)","Psychological Distress","Digital Health","Mindfulness-Based Interventions","Coping Skills","AI-Guided Intervention","Virtual Reality (VR)","Immersive Technology","2026-05-07",{"date":564,"type":35},"2026-05-12",{"date":566,"type":35},"2026-03-29",{"date":568,"type":24},"2026-05-30",{"name":41,"class":42},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":19,"minAge":442,"maxAge":77,"enrollmentInfo":577,"targetDuration":4,"studyType":25,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":594,"locationsCount":43},"100621290","active-oxygen-releasing-gel-with-photodynamic-therapy-in-treating-stage-iii-periodontitis-100621290","NCT07368699","Active Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis","Evaluation of Active Oxygen Releasing Gel Combined With Photodynamic Therapy in The Treatment of Stage III Periodontitis (A Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* Patients with periodontal diagnosis of stage III periodontitis\n* Patients with residual periodontal pocket depth ≥4 mm ,CAL≥ 5mm with bone loss extending to middle third of root and beyond in radiography\n* Bleeding on probing at least four sites at base-line\n* Patients who didn't receive periodontal treatment for a minimum of 3 months prior to the examination.\n* Patients of both sexes aged ≥30 and ≤70 years\n\nExclusion Criteria:\n\n* Smokers or those with any other harmful habits such as pipe or vape smoking\n* Patients with any systemic condition that will possibly affect the outcome of periodontal therapy i.e. (diabetic patients)\n* Patients who have received any local or systemic anti-inflammatory medications or antibiotics within the last 6 months\n* Pregnant or lactating women\n* Patients with parafunctional habits",{"count":578,"type":24},42,[27],"Periodontitis is a serious gum disease that can damage the tissues supporting the teeth. The standard treatment is scaling and root planing of the teeth and roots. However, in some patients, this treatment alone may not fully control inflammation and harmful bacteria.\n\nThis study aims to evaluate whether adding an active oxygen-releasing gel, with or without photodynamic therapy, improves treatment outcomes in patients with stage III periodontitis. The oxygen-releasing gel is applied to the gums and releases oxygen, which may help reduce harmful bacteria. Photodynamic therapy uses a light source together with a special dye to target and destroy bacteria and improve gingival health.\n\nIn this randomized clinical trial, 42 patients with stage III periodontitis will be divided into three groups. One group will receive standard scaling and root planing (SRP) plus the oxygen-releasing gel. A second group will receive standard scaling and root planing (SRP)plus the gel and photodynamic therapy. The third group will receive standard scaling and root planing(SRP) only.\n\nGum health will be evaluated by measuring gingival index, bleeding index, pocket depth, and supra crestal tissue attachment level at the start of the study and after one and three months. Microbiological samples from periodontal pockets will also be used to assess levels using quantitative Polymerase Chain Reaction (qPCR) for relative abundance of Treponema denticola and Porphyromonas gingivalis bacteria related to periodontal disease.",[582],"Stage III Periodontitis",[584,585,586,587],"Active oxygen releasing gel","Photodynamic therapy","Periodontitis","Scaling and Root Planing,","2026-04-26",{"date":590,"type":35},"2026-04-28",{"date":592,"type":35},"2025-01-26",{"date":431,"type":24},{"name":41,"class":42},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":19,"minAge":602,"maxAge":419,"enrollmentInfo":603,"targetDuration":4,"studyType":25,"phases":604,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":43},"100633188","effect-of-intranasal-dexmedetomidine-on-the-incidence-of-emergence-agitation-in-children-undergoing-strabismus-surgery-100633188","NCT07523438","Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery","Effect of Two Different Doses of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery , A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age: 3-6 years, both sexes\n* ASA physical status class I , II.\n\nExclusion Criteria:\n\n* history of neurological and psychiatric disease\n* body mass index \\> 20 kg m-2\n* allergy to dexmedetomidine\n* patients on medical treatment which has any sedative effect\n* mentally retarded children","3 Years",{"count":248,"type":24},[27],"Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg \u002Fkg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg\u002Fkg",[192,607],"Emergence Agitation",[192,609,610],"emergence agitation","strabismus surgery","2026-04-05",{"date":613,"type":35},"2026-04-13",{"date":615,"type":35},"2026-03-01",{"date":617,"type":24},"2026-12-01",{"name":41,"class":42},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":25,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":635,"leadSponsor":636,"locationsCount":43},"100629556","sialendoscopy-versus-photobiomodulation-in-prevention-of-radiation-induced-xerostomia-100629556","NCT07476209","Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia","Sialendoscopic Management Versus Photobiomodulation in Prevention of Radiation-induced Xerostomia in Head and Neck Cancer Patients (Randomized Clinical Trial)","Inclusion Criteria:\n\n* Patients who are going to receive (IMRT) as a treatment of (HNC) either as postoperative (adjuvant) therapy or definitive therapy.\n* Patients who are planned to receive (RT) with parotid mean dose bilaterally not exceeding 25 Gy.\n* Males and females with an age not less than 18 years30\n\nExclusion Criteria:\n\n* Patients suffering from uncontrolled systemic diseases (such as diabetes, hypertension, cardiovascular, liver or renal dysfunction).\n* Patients with history of using drugs such as (pilocarpine ), oral humidifiers or herbs that prevent or treat xerostomia 2 months prior to study inclusion.\n* Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.\n* Patients diagnosed with Sjögren's disease or other underlying systemic illness that is known to cause xerostomia.",{"count":578,"type":24},[27],"Radiation induced xerostomia (RIX) represents a common debilitating side effect for (RT), adversely affecting oral health and hindering head and neck cancer (HNC) patients' quality of life (QOL). To date, managing (RIX) is mainly symptomatic, while the only FDA-approved preventive therapeutic agent is Amifostine, with associated systemic toxicities. Sialendoscopic management is a minimally invasive technique that can help in restoring ductal patency, decreasing inflammation and improving salivary flow. Laser Photobiomodulation (PBM) is a noninvasive approach that enhances salivary gland function by stimulating cellular activity, increasing blood flow and attenuating oxidative stress.\n\nAim: The present study aims to evaluate and compare the efficacy of sialendoscopic management and photobiomodulation in managing (RIX) in (HNC) patients.\n\nMaterials and Methods: A randomized clinical trial will be carried out on 42 (HNC) patients. Directly prior to the first (RT) session, Group I (n= 14 patients) will receive sialendoscopic management. Group II (n=14 patients) will receive (PBM) sessions. Group III (n= 14 patients) will receive basic oral care (BOC). Xerostomia will be evaluated at baseline, at 3 weeks and after 8 weeks from the end of (RT), clinically using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and objectively using unstimulated salivary flow. Quality of life will be assessed using Multidisciplinary Salivary Gland Society (MSGS) questionnaire. Salivary amylase will be assessed at baseline and after 8 weeks from the end of (RT).",[630],"Radiation Induced Xerostomia","2026-03-22",{"date":633,"type":35},"2026-03-25",{"date":456,"type":24},{"date":458,"type":24},{"name":41,"class":42},""]